The corporate venturing arm of GlaxoSmithKline has joined peer Merck in backing a genetic diagnostics company. One of Glaxo's executives has joined HTG's board.
The corporate venturing arm of drugs company GlaxoSmithKline (GSK) has joined peer Merck in the latest $16.2m round raised by US-based medical company HTG Molecular Diagnostics.
GSK’s SR One joined the second tranche of HTG’s series D round financing, which was led by Denmark-based foundation Novo and also included Merck Capital Ventures, the corporate venturing unit of the eponymous drugs company, early stage investor Solstice Capital and US venture capital firm Valley Ventures.The first tranche was announced in February.
…
